It is conceivable that differences in compositional stability and species richness between grass- and shrub-dominated areas are a function of different environmental conditions [1].
Thus it is conceivable that differences in response are attributable to clinician differences rather than patient ones.
Consequently, it is conceivable that differences observed herein could be explained, at least in part, by age rather than RA.
It is conceivable that differences in background risk factor profiles (menopausal status, reproductive factors, obesity, or dietary intake) contribute to these variations.
It is conceivable that differences in substrate specificity between G4 helicases target the enzymes to distinct G4 structures with alternate configurations.
Thus, it is conceivable that differences in cumulative contour length (i.e., differences in the amount of edges) or perceptual load between small and large non-symbolic stimuli might have caused the N1 effects observed here.
It is conceivable that differences in lifestyle between these groups could influence exposure or that there is increased susceptibility in older age, leading to differential observed effects of BS on CDPs.
So, it is conceivable that differences in Ang-2 levels present before chemotherapy, which have been shown to be associated with disease-free survival in high-risk myeloid malignancies [ 42], might have influenced our results.
It is conceivable that differences in p53 status have an impact on differences in the sensitivity of cells to MN-inducing agents, although evidence from experiments with p53 deficient variants of human TK6 cells have revealed little influence of p53 status on MN formation (Hashimoto et al. 2011; Honma and Hayashi 2011).
It is conceivable that differences in the results from the EXTREME and SPECTRUM trials may also be due in part to the two different EGFR monoclonal antibodies used, namely cetuximab (a chimeric human/murine IgG1 antibody) and panitumumab (a fully human IgG2 EGFR antibody).
